The AP1S1 Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the AP1S1 gene in human HeLa cells. This heterogeneous pool enables loss-of-function studies of the sigma1A subunit of the adaptor protein complex 1 (AP-1), providing a model that avoids clone-specific artifacts and reflects population-level responses.
HeLa is an epithelial cervical adenocarcinoma cell line harboring integrated HPV-18 DNA, which inactivates p53 and drives genomic instability. It is a widely used model for cancer biology, gene function, and drug response studies due to its robust growth and extensive characterization.
AP1S1 encodes the sigma1A subunit of the AP-1 complex, which includes AP1B1, AP1G1, and AP1M1. AP-1 is recruited by ARF1 GTPase and PI4P to mediate clathrin-dependent vesicle formation and cargo sorting between the trans-Golgi network (TGN) and endosomes. Sigma1A recognizes tyrosine-based YXX?? motifs on proteins such as mannose-6-phosphate receptors (M6PR, IGF2R), lysosomal enzymes (cathepsins), LAMP1, and LDL receptor-related proteins. Knockout disrupts this trafficking, mislocalizing these targets and impairing lysosomal function. AP-1 activity is regulated by ARF1, PI4P, and receptor tyrosine kinase signaling.
In HeLa cells, AP1S1 loss permits study of adaptor dysfunction in a background of p53 inactivation and genomic instability. The trafficking defects can alter lysosomal activity, autophagy, and surface receptor distribution??processes relevant to cancer progression and drug resistance. This model is particularly informative for MEDNIK syndrome, a neurodevelopmental disorder linked to AP1S1 mutations.
Research applications include exploration of clathrin-mediated endocytosis, retrograde transport, lysosomal storage disorders, and neurodegenerative diseases. Assays such as immunofluorescence for TGN-46 or LAMP1, transferrin uptake, lysosomal enzyme activity, co-immunoprecipitation, and RNA-seq are well suited. This polyclonal knockout tool supports detailed mechanistic and pharmacological studies. For further information, please contact Ascent Research.
